Skip to content
An Initiative of AVAC In partnership with Access Bridge
Search

Resource Library

The PrEPWatch Resource Database offers a wide range of material on the status of PrEP as an option for biomedical HIV prevention around the world. Search this database to find step-by-step guidance for rolling out PrEP, summaries of the research to date on safety, efficacy and implementation, tools to assist planning and roll out, country updates on PrEP policy and access, and lessons learned from those efforts.

Filter By
Multiple filters can be used at once

Showing results 51 - 60 of 158

Selected Filters:
14 June 2024

Generic CAB for PrEP Development and Access

This presentation from Medicines Patent Pool explains the process of licensing, developing, and manufacturing generic cabotegravir (CAB) for PrEP, including expected timelines for generic CAB for PrEP availability.

Community/Advocacy

Presentation
10 June 2024

HPTN 083-02: Factors influencing adherence to injectable PrEP and retention in an injectable PrEP study

This article from Journal of the International AIDS Society to explores the experiences of participants in the HPTN-083 trial, which evaluated safety and efficacy of cabotegravir for PrEP, including barriers to adherence and other factors that may have impacted study implementation or outcomes.

Research

External Link
3 June 2024

Leading the Way: Early learnings from CAB for PrEP introduction in Zambia and Zimbabwe

Slides / Recording Programmatic rollout of long-acting injectable cabotegravir (CAB for PrEP) has launched in Zambia and Zimbabwe! Recommended by the World Health Organization as a safe and effective HIV prevention method in 2022, these two countries are now the first in Africa to incorporate this new, long-awaited PrEP product into their national HIV prevention…

Service Delivery

Event
28 May 2024

MOSAIC (Maximizing Options to Advance Informed Choice for HIV Prevention)

Short introduction to MOSAIC, a project working across multiple countries to implement user-centered research and research translation efforts to identify, understand, and remove barriers to new product introduction, access, and use; coordinate and provide technical assistance to global, national, and subnational stakeholders to expedite product launch and scale-up; and strengthen the capacity of a wide…

Research

Document
7 May 2024

AfroCAB’s Frequently Asked Questions on Cabotegravir for PrEP

This document, produced by AfroCAB, answers frequently asked questions that users may have about cabotegravir (CAB) for PrEP.

Community/Advocacy

Document
26 April 2024

Coordinating Implementation Science for CAB for PrEP: Linking Modellers with the Latest Implementation Science Evidence, March 2024

This document summarises key takeaways from a March 2024 BioPIC Think Tank to ensure modellers and implementation science researchers remain aligned on the latest cabotegravir for PrEP data and evidence.

Research

Document
25 April 2024

Coordinating Implementation Science: Taking Stock of PrEP Evidence

This document summarises key takeaways from the BioPIC Think Tank held in March 2024 to review existing PrEP evidence and evidence gaps to date.

Research

Document
9 April 2024

Opportunities for Pharmacist-Delivered Injectable PrEP in the USA

These Quick Take briefings from Georgetown University’s O’Neill Institute for National and Global Health Law provide insights on barriers and opportunities for pharmacist-administered injectable PrEP in the USA, including delivery via mobile pharmacies.

Research, Service Delivery

Document
2 April 2024

Private Sector Market Assessment: Eswatini

This market assessment explores the opportunities and barriers to leveraging private sector channels to expand access to new and existing pre-exposure prophylaxis (PrEP) methods, including oral PrEP, the dapivirine vaginal ring (PrEP ring), and long acting cabotegravir (CAB PrEP) in Eswatini.

Service Delivery

Document
1 April 2024

CAB PrEP Introduction Situation Analysis – Zimbabwe – 2023

This document summarizes findings from the national situation analysis that can support the creation of a national biomedical HIV prevention platform. It aims to clarify critical steps for the introduction of biomedical HIV prevention products.

Service Delivery

Document